Complimentary access to the JTO and a 25% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 15.609, JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports. JTO CRR is indexed in PubMed Central.
JTO by the Numbers
13
out of 242 in 2020 Oncology Journals
4
out of 64 in 2020 Respiratory Journals
15.609
Impact Factor (up from 13.357 in 2019)
1,704%
increase in 6 years full-text article downloads
Recent journal articles
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients with Treatment-Naïve Advanced ALK-Positive NSCLC
Percutaneous Image-guided Biopsy for a Comprehensive Hybridization Capture-based Next-generation Sequencing in Primary Lung Cancer: Safety, Efficacy, and Predictors of Outcome
Automating Access to Real World Evidence
Functional Trajectories & Resilience among Adults with Advanced Lung Cancer
A phase II clinical trial of combination nivolumab, ipilimumab, and paclitaxel in patients with untreated metastatic non-small cell lung cancer: The OPTIMAL Trial
Severe Pulmonary Toxicity with Concurrent Anlotinib And Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: The ALTER-L042 Phase I Clinical Trial
Genomic and transcriptomic analysis of neuroendocrine transformation in ALK-rearranged lung adenocarcinoma after treatments with sequential ALK inhibitors: a brief report
Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to journals@iaslc.org.
New JTO Collections
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.